On January 12, the International Generic and Biosimilar Medicines Association (IGBA) announced that Vivian Fritelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa, will be the next IGBA Chair for 2022. The IGBA represents manufacturers of generic and biosimilars medicines around the world, and “works to improve patients’…
On December 8, Samsung Bioepis announced that it had presented the longest follow-up study results for a trastuzumab biosimilar in patients with HER2-positive early or locally advanced breast cancer. The five-year study compared long-term survival rates of patients on SB3 (ONTRUZANT®, Samsung Bioepis’ biosimilar of Herceptin®) and Herceptin® (trastuzumab) from…